Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WGA-800CW is a lectin-based fluorescent imaging agent developed for the detection of esophageal dysplasia in patients with Barrett's esophagus. It consists of Wheat Germ Agglutinin (WGA), a lectin that binds specifically to N-acetyl-D-glucosamine and sialic acid residues, conjugated to the near-infrared fluorescent dye IRDye 800CW. When topically administered via a spray catheter during endoscopy, WGA-800CW binds to glycans that are differentially expressed in dysplastic tissue compared to normal mucosa. This allows for real-time visualization of otherwise invisible lesions using quantitative fluorescence molecular endoscopy (qFME) or optical coherence tomography-near-infrared fluorescence (OCT-NIRF) imaging systems. The agent is currently being evaluated in phase 1 clinical trials to determine the optimal dose and safety for detecting invisible esophageal dysplasia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on WGA-800CW.